ALK and non-small cell lung carcinoma: However, progress of research, clinicians found that the overall efficacy of first-line immunotherapy in NSCLC patients with partial driver gene mutations was poor, and the efficacy of EGFR/ALK mutation patients receiving ICI treatment was limited, even some patients experienced hyperprogression8, but there were still many case reports that such populations could benefit from immunotherapy.